Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial -

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Information type: Randomised controlled trials
Source: Lancet Public Health
Specialities: Respiratory disorders
Summary
Results of this study (n=809) show that compared with placebo, benralizumab reduced the annual asthma exacerbation (in patients with eosinophil counts >300cells/microL) rate over 48 weeks when given every 4 weeks (rate ratio 0.55, p<0.0001) or every 8 weeks (0.49, p<0.0001).
UKMi comment
Benralizumab is a monoclonal antibody that binds to the interleukin-5 receptor that depletes eosinophils.

A related editorial discusses the findings of this study, as well as the CALIMA study.
Related links: Editorial